4'-aminomethyl-[1,1'-biphenyl]-4-carboxylic acid | 380228-55-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4'-aminomethyl-[1,1'-biphenyl]-4-carboxylic acid
• 英文别名: 4'-(Aminomethyl)biphenyl-4-carboxylic acid；4-[4-(aminomethyl)phenyl]benzoic acid
• CAS: 380228-55-7
• 化学式: C₁₄H₁₃NO₂
• 分子量: 227.263
• InChiKey: DHPXOOZAUQHRKS-UHFFFAOYSA-N

物化性质

• 熔点：
  >300 °C
• 沸点：
  431.3±38.0 °C(Predicted)
• 密度：
  1.213±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  7-chloro-2-ethylimidazo[1,2-a]pyridine-3-carboxylic acid 、 4'-aminomethyl-[1,1'-biphenyl]-4-carboxylic acid 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 4′-{(7-chloro-2-ethylimidazo[1,2-a]pyridine-3-carboxamido)methyl}-[1,1′-biphenyl]-4-carboxylic acid
  参考文献：
  名称：

  Lead Optimization of a Novel Series of Imidazo[1,2-a]pyridine Amides Leading to a Clinical Candidate (Q203) as a Multi- and Extensively-Drug-Resistant Anti-tuberculosis Agent

  摘要：

  A critical unmet clinical need to combat the global tuberculosis epidemic is the development of potent agents capable of reducing the time of multi-drug-resistant (MDR) and extensively-drug-resistant (XDR) tuberculosis therapy. In this paper, we report on the optimization of imidazo[1,2-a]pyridine amide (IPA) lead compound 1, which led to the design and synthesis of Q203 (50). We found that the amide linker with IPA core is very important for activity against Mycobacterium tuberculosis H37Rv. Linearity and lipophilicity of the amine part in the IPA series play a critical role in improving in vitro and in vivo efficacy and pharmacokinetic profile. The optimized IPAs 49 and 50 showed not only excellent oral bioavailability (80.2% and 90.7%, respectively) with high exposure of the area under curve (AUC) but also displayed significant colony-forming unit (CFU) reduction (1.52 and 3.13 log10 reduction at 10 mg/kg dosing level, respectively) in mouse lung.

  DOI：

  10.1021/jm5003606
• 作为产物：
  描述：

  4-(N-trifluoroacetyl)aminomethylphenylboronic acid 在 四(三苯基膦)钯 potassium fluoride 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 20.0h， 生成 4'-aminomethyl-[1,1'-biphenyl]-4-carboxylic acid
  参考文献：
  名称：

  设计，合成和验证生物活性肽的刚性接头

  摘要：

  合成了可变长度的刚性接头，并将其用于连接两个NDP-α-MSH配体。通过固相合成引入接头。生物学评估表明，这些接头实际上对配体与人类黑皮质素4受体的结合没有影响。

  DOI：

  10.1016/j.tetlet.2005.08.151

文献信息

• [EN] CCR10 ANTAGONISTS<br/>[FR] ANTAGONISTES DE CCR10
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2009052078A1

  公开（公告）日：2009-04-23

  The invention relates to a compound of formula (I) or a tautomer thereof or a pharmaceutically acceptable salt thereof, wherein R1 to R11, W, X, Y, Z, and n are as defined herein. The invention also relates to methods of using the compounds of formula (I) and compositions thereof to treat various diseases and disorders in a patient. The invention also relates to processes for preparing the compounds of formula (I) and intermediates useful in these processes.

  该发明涉及公式（I）的化合物或其互变异构体或其药学上可接受的盐，其中R1至R11，W，X，Y，Z和n如本文所定义。该发明还涉及使用公式（I）的化合物及其组合物治疗患者的各种疾病和障碍的方法。该发明还涉及制备公式（I）化合物和在这些过程中有用的中间体的方法。
• Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
  申请人：Fan Hong

  公开号：US20050147555A1

  公开（公告）日：2005-07-07

  Methods for the preparation of multivalent constructs for therapeutic and diagnostic applications are provided. More specifically, novel methods for preparing multivalent constructs comprising the formula A-B-C-D-E-B′-F for therapeutic and diagnostic applications are provided which use a novel linker D comprising, in various embodiments, a dicarboxylic acid derivative such as, e.g., a glutaric acid bis N-hydroxysuccinimidyl ester or a derivative therof; or a diamine derivative. The remaining components in the multivalent construct A-B-C-D-E-B′-F are defined as follows: A is a first peptide, B is a first branching group, C is an optional first spacer, E is an optional second spacer which may be the same as or different from said first spacer C, B′ is an optional second branching group which may be the same as or different from said first branching group B, and F is a second peptide which may be the same as or different from said first peptide A.

  提供了制备用于治疗和诊断应用的多价构建物的方法。更具体地，提供了用于制备多价构建物的新方法，其包括公式A-B-C-D-E-B'-F，其中使用了一种新的连接剂D，该连接剂D包括各种衍生物，例如戊二酸双N-羟基琥珀酰亚胺酯或其衍生物；或者是一种二胺衍生物。多价构建物A-B-C-D-E-B'-F中的其余组分定义如下：A是第一肽，B是第一分支基团，C是可选的第一间隔物，E是可选的第二间隔物，可以与第一间隔物C相同或不同，B'是可选的第二分支基团，可以与第一分支基团B相同或不同，而F是第二肽，可以与第一肽A相同或不同。
• Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases(ptps)
  申请人：Swinnen Dominique

  公开号：US20050124656A1

  公开（公告）日：2005-06-09

  The present invention is related to substituted methylene amide derivatives of formula (I) and use thereof for the treatment and/or prevention of metabolic disorders mediated by insulin resistance or pyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of substituted methylene amide derivatives of formula (I) to modulate, notably to inhibit the activity of PTPs. Also the present invention relates to a method of treating diabetes type II, obesity and to regulate the appetite of mammals. The present invention is furthermore related to novel substituted methylene amide derivatives and method of preparation thereof. Formula (I).

  本发明涉及公式（I）的取代亚甲基酰胺衍生物及其用于治疗和/或预防由胰岛素抵抗或高血糖引起的代谢障碍，包括1型和/或2型糖尿病、不足的葡萄糖耐受性、胰岛素抵抗、高脂血症、高三酰甘油血症、高胆固醇血症、肥胖症、多囊卵巢综合症（PCOS）。特别是，本发明涉及使用公式（I）的取代亚甲基酰胺衍生物来调节，尤其是抑制PTP的活性。本发明还涉及一种治疗2型糖尿病、肥胖症和调节哺乳动物食欲的方法。此外，本发明还涉及新的取代亚甲基酰胺衍生物及其制备方法。公式（I）。
• SUBSTITUTED METHYLENE AMIDE DERIVATIVES AS MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS)
  申请人：Applied Research Systems ARS Holding N.V.

  公开号：EP1470102A1

  公开（公告）日：2004-10-27
• METHODS FOR PREPARING MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS
  申请人：BRACCO International B.V.

  公开号：EP1778299A2

  公开（公告）日：2007-05-02